Avantor 3Q 2026: Revenue $1.7B, Net income $203.4M, EPS $0.3— 10-Q Summary

Avantor reported Q3 2026 net sales of $1.7B, up 4.6% YoY, and net income of $203.4M, reversing a prior-year loss. EPS was $0.3, compared to a loss of $1.04. Organic sales grew 5.2%, led by VWR Distribution. Risks include trade policy and inflation.

Original reporting
Published Oct 28, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Avantor 3Q 2026: Revenue $1.7B, Net income $203.4M, EPS $0.3— 10-Q Summary — source image
Decision brief

The 30-second read

$AVTRNeutralMed
01

Why it matters

The earnings release may drive short‑term price movement, with upside potential tempered by cost pressures.

02

Market read

The report is a primary earnings disclosure for a mid‑cap U.S. listed company, offering new data that could influence trading decisions today.

03

What to watch

Potential impact of trade‑policy uncertainty on VWR goodwill valuation and future organic growth.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Avantor's Q3 2026 10‑Q provides the first detailed financial snapshot for the quarter, highlighting a shift from loss to profit and outlining operational risks.

Company-level read

Ticker impact

$AVTRNeutralHigh confidence
Context

Avantor posted Q3 2026 results showing $1.7B sales and a swing to $203.4M net income, the first public disclosure of these numbers.

Expected impact

modest upside as investors price the earnings beat, though margin compression could limit gains

Evidence & confidence

Revenue grew 4.6% YoY and the company turned a loss into profit, which typically supports a short-term price rise, but lower gross margin and higher costs introduce downside risk.

Market effects

Positive for the broader life‑science supplies sector as Avantor's turnaround may signal demand recovery.

U.S. market may see a modest lift in related biotech and lab‑equipment stocks.

Limited; primarily impacts U.S. listed specialty chemicals and lab‑services investors.

Counterpoint

Margin compression and inflation risks could outweigh the earnings beat, leading to a sell‑off.

Key entities

  • Avantor, Inc.

    U.S. life‑science and specialty chemicals provider reporting Q3 2026 results.

Related articles

$AVTRMedAI 8/10

Avantor Inc (AVTR) Q3 2026 Earnings Call Highlights: Return to Organic Growth, Raised

Avantor Inc (AVTR) reported Q3 2026 earnings, highlighting organic growth and raised guidance. CEO Emmanuel Ligner expressed confidence in 2027, citing strong momentum. CFO Todd Garner forecasted Q4 revenue growth of 2.5% to 4.5%, with VWR growing mid-single-digits. AI is seen as a potential tailwind. Margins faced pressure from mix and inflation, but EBITDA margin expansion is expected to continue. Investments in facilities and AI tools are ongoing, with returns anticipated over time.

$AVTRHighAI 8/10

What Avantor (AVTR) Said on Its Q3 Earnings Call

Avantor (AVTR) reported Q3 revenue of $465M for its Bioscience & Medtech Products segment, up 3.6% organically. Adjusted operating income was $123M with a 26.6% margin. The company raised its 2026 organic revenue growth outlook to 0.75-1.25% and increased its adjusted EPS and free cash flow projections. Avantor aims to reduce net leverage below 3x by year-end.

$AVTRHighAI 8/10

Avantor (AVTR) Q3 2026 Earnings Call Transcript

Avantor (AVTR) reported Q3 2026 earnings, exceeding expectations with $1.698B revenue (5.2% organic growth) and $0.22 adjusted EPS. VWR and BMP segments showed strong performance, driving growth. The company raised full-year guidance and aims to reduce leverage below 3x by year-end. Revival initiatives are improving execution and end-market demand.

$AVTRMedAI 8/10

Avantor beats Q3 estimates but shares slip on guidance

Avantor Inc. (NYSE: AVTR) reported Q3 adjusted EPS of $0.22, beating estimates by $0.01, with revenue of $1.70B, up 4.6% YoY. Shares fell 2.6% as guidance matched expectations. The company raised its full-year organic revenue growth and free cash flow outlooks. Organic revenue grew 5.2% YoY, with segments showing varied performance.